Search Results for "apomorphine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for apomorphine. Results 11 to 12 of 12 total matches.
See also: Apokyn
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
) for Parkinson’s disease. Med Lett
Drugs Ther 2020; 62:20.
4. Sublingual apomorphine (Kynmobi) for Parkinson’s ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Safinamide (Xadago) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
.
Subcutaneous apomorphine can be used for rescue
treatment of “off” episodes. Deep brain stimulation ...
The FDA has approved the monoamine oxidase
type B (MAO-B) inhibitor safinamide (Xadago – US
Worldmeds) as an adjunct to levodopa/carbidopa
for management of "off" episodes in patients with
Parkinson’s disease (PD). It is the first reversible
MAO-B inhibitor to be approved for this indication.
Selegiline (Eldepryl, and others) and rasagiline
(Azilect, and generics), two irreversible MAO-B
inhibitors, have been used alone and as adjuncts to
levodopa/carbidopa for many years. Safinamide is
not approved for use as monotherapy.